18 results about "With glomerular filtration rate" patented technology

Verdazil derivative compounds and compositions thereof, useful as contrast agents for biomedical imaging, are provided. The compounds and compositions of this disclosure can be used, for example, for quantitative and / or qualitative assessment of glomerular filtration rate (GFR) in subjects, providing a reliable and rapid assessment of renal function.

A system and method for diagnosing a patient's renal function, the method comprising delivering a first tracer agent, transmucosally applying a first excitation light to the first tracer agent at the first monitoring site, transmucosally receiving a first fluorescent light emitted from the first tracer agent at the first monitoring site, transforming the received first fluorescent light to produce a first fluorescence signal, processing the first fluorescence signal to determine a first decay rate, and processing the first decay rate of the first fluorescent light to determine a glomerular filtration rate of the patient.

The present invention consists of a digital, always-online computer system designed to optimize perioperative safety through the automated integration of clinical and laboratory parameters. Unlike conventional medical calculators, this system implements a reactive logic engine that simultaneously calculates glomerular filtration rate (CKD-EPI 2021) and scores multiple risk scales (Goldman, LEE, ASA, CHA2DS2-VASc, HAS-BLED) without duplicate data entry. The system includes a drug reconciliation algorithm that cross-references the bleeding risk of the surgical procedure with the patient's renal function, generating accurate recommendations for discontinuing or continuing high-risk medications (anticoagulants, antiplatelet agents, SGLT2 inhibitors) based on current clinical evidence.

This invention relates to compositions and methods relating to a combination of naturally-occurring active ingredients useful for the regulation of kidney and excretory system function. The combination of active ingredients, comprising vitamin B6, vitamin E, iron, roundhead lespedeza, birch leaf, and red bilberry, improves the function of kidney structures. The present invention may be used to achieve lower blood nitrogen content, including help to eliminate creatinine, urea, uric acid, by improving glomerular filtration and thus delaying hemodialysis. The present invention may be used to achieve a pronounced anti-inflammatory effect on the kidneys and the urinary tract. The present invention may also be used on its own or as a part of conventional treatment for a long time or indefinitely.

The invention discloses a multi-database data management method and system for IgA nephropathy treatment, and relates to the technical field of data management. According to the method, multi-source clinical data is collected, a structured data set is formed based on data quality scoring and conflict resolution, the disease course stage of a patient is dynamically recognized based on a biomarker and a glomerular filtration rate, and differentiated collection, storage, synchronization and access strategies based on the disease course stage of the patient are specifically generated; multi-database collaborative management is executed, and the management effect is iteratively optimized through the data collection integrity rate, the data synchronization timeliness rate, the storage resource utilization rate and the response time; the problem that the IgA nephropathy multi-source database management and synergy efficiency is low is effectively solved, and the accuracy and efficiency of IgA nephropathy multi-source data management are remarkably improved.

The invention provides a glomerular filtration rate estimation method and device for a patient with asymmetric double renal functions. The method comprises the following steps: acquiring basic information, clinical data, laboratory detection data and iconography data of a patient, wherein the iconography data comprises kidney volume, blood flow volume, cortex and medullary thickness and kidney function expression of the right kidney and the left kidney; by analyzing iconography data, a functional difference measurement coefficient for quantifying the asymmetry of double kidney functions is calculated. Thirdly, extracting a global feature vector of the patient by using a deep learning model, and performing fusion processing on the iconography data, the clinical data and the laboratory detection data to generate a comprehensive feature vector; and on the basis, the functional weights of the right kidney and the left kidney are adjusted according to the functional difference measurement coefficient, finally, the adjusted functional weights and the global feature vectors are input into a deep regression model, and a corrected GFR estimated value is obtained through calculation. And more accurate renal function evaluation can be provided according to the condition that double renal functions are asymmetric.

Systems, devices, and methods involve approaches for determining a calibration value for an individual, estimating a creatinine level using a chemical sensor (e.g., based on an optical property of a chemical sensor), and estimating a glomerular filtration rate (GFR) based, at least in part, on the calibration value and the creatinine level.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a traditional Chinese medicine composition for treating chronic kidney disease and its application. Its main active ingredients, by weight, include: Astragalus membranaceus 20-35 parts, Cuscuta chinensis 10-25 parts, Codonopsis pilosula 10-25 parts, Atractylodes macrocephala 10-20 parts, Poria cocos 10-25 parts, Dioscorea opposita 10-25 parts, Salvia miltiorrhiza 10-25 parts, and Coix lacryma-jobi 10-30 parts. Real-world cohort studies have shown that this traditional Chinese medicine composition for treating chronic kidney disease can significantly improve the survival rate of patients with chronic kidney disease, delay the decline in glomerular filtration rate, effectively reduce the risk of kidney disease progression, and has good safety.

A method, system, and medium for dynamically controlling infusion drip rate based on patient physiological parameters include: acquiring real-time physiological parameter data, medical history data, and drug attribute data of the patient; real-time physiological parameter data including glomerular filtration rate and B-type natriuretic peptide concentration; obtaining a safe drip rate range based on one or more of the real-time physiological parameter data, medical history data, and drug attribute data according to a preset rule base; calculating a recommended drip rate based on a machine learning model and a standard drip rate; obtaining a preset drip rate threshold range, and generating and outputting a first drip rate control command based on the recommended drip rate, the safe drip rate range, and the preset drip rate threshold range; monitoring the actual drip rate in real time and calculating the error value between the actual drip rate and the recommended drip rate; and dynamically adjusting the first drip rate control command based on the error value using a closed-loop control algorithm to generate and output a second drip rate control command.

Methods, systems, and apparatus for determining glomerular filtration rate (GFR) by acquiring a measurement dataset. Furthermore, this disclosure includes: acquiring a measurement dataset comprising multiple measurement entries acquired before and after administration of an exogenous fluorescent agent; generating an intrinsic fluorescence (IF) signal, the IF signal representing the detected fluorescence intensity emitted from the exogenous fluorescent agent within a diffuse reflective medium; determining whether the IF signal includes a portion of early fluorescence data; after determining this portion of the early fluorescence data, identifying an operable IF signal range by filtering the IF signal associated with the early fluorescence data; determining a GFR value in the patient based on the rate of change of the operable IF signal; and providing the GFR value.

The invention discloses a pharmaceutical composition for treating chronic kidney disease stage 1-3 as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition consists of 40-60 parts of astragalus membranaceus, 40-60 parts of black soybeans, 8-12 parts of angelica sinensis, 24-36 parts of dogwood and 8-12 parts of rhodiola rosea. The preparation method comprises the following steps: pretreating the raw materials, soaking, boiling for several times and filtering to obtain a finished product. Based on the treatment principles of tonifying qi, activating blood, dredging collaterals and removing blood stasis in traditional Chinese medicine, the traditional Chinese medicine composition conforms to the pathogenesis of chronic kidney disease deficiency in root and excess in superficies, all the components synergistically play a role, the serum urea nitrogen, serum creatinine level and glomerular filtration rate of a patient can be improved and edema, weakness and other symptoms can be relieved by combining basic treatment, the total effective rate reaches 83.33%, and the traditional Chinese medicine composition is good in safety, easy and convenient to prepare and suitable for clinical application. The traditional Chinese medicine composition is suitable for long-term administration of patients with spleen and kidney qi deficiency and blood deficiency with stasis syndrome type chronic kidney diseases at 1-3 stages, and has good application value in treatment of related diseases.

The invention provides a method and a model for predicting the risk of early renal function decline after renal partial resection of a renal cell carcinoma patient. According to the method, clinical parameters of a patient are obtained through a preoperative nomogram or preoperative-intraoperative combined nomogram prediction model, risk integrals of all the parameters are distributed, a total integral is calculated, and the postoperative early renal function decline prediction probability is determined and visually output. The parameters of the preoperative nomogram prediction model comprise age, diabetes history, preoperative estimated glomerular filtration rate, kidney score and radiomics score; the joint model newly increases the intra-operative ischemia time. Model construction comprises the steps of CT image standardization, region segmentation, radiology feature extraction and preprocessing and the like, and can assist in clinical accurate assessment of risks and optimization of treatment decisions.

The application provides a kind of prediction method and model of early renal function decline risk of renal cell carcinoma patient after partial nephrectomy.Methods obtain patient clinical parameters by preoperative nomogram or preoperative-intraoperative joint nomogram prediction model, assign each parameter risk score and calculate total score, determine the prediction probability of early postoperative renal function decline and can be visualized output.Preoperative nomogram prediction model parameters include age, history of diabetes, preoperative estimated glomerular filtration rate, kidney score and radiomics score;Intraoperative ischemia time is added to the joint model.Model construction is standardized by CT image, region segmentation, radiology feature extraction and preprocessing, etc., which can assist clinical precise risk assessment and optimize treatment decision.

The present application relates to the technical field of health care informatics, and discloses an osteoporosis prevention strategy analysis method and system, comprising: a discrete event sequence extraction module extracts clinical events from electronic medical records; a parameter self-adaptive mapping module constructs a time scale scaling factor using glomerular filtration rate to correct the decay parameter of the risk pulse function in reverse, and establish a positive correlation mapping between the decay rate and the clearance efficiency; a time domain superposition analysis module calculates the instantaneous bone loss index and generates the bone density evolution trajectory; and a strategy reverse optimization module simulates intervention superposition to screen the optimal strategy. The present application converts physiological metabolism indicators into time control variables of mathematical models, avoids kinetic distortion caused by individual metabolic differences, and realizes the quantification and early warning of the risk long tail superposition effect in patients with reduced metabolic function.

The use of traditional Chinese medicine in the manufacture of drugs to prevent and treat nephritis. This traditional Chinese medicine is made from Taraxacum officinale, Polygonum cuspidatum, Sonchus oleroseus L., and Scutellariae barbatae Herba. Danio rerio fish was adopted as a model. Animal experiments have proven that traditional Chinese medicine can help. It is used to treat nephritis caused by aristolochic acid, protect kidney function and / or reduce edema in renal dysfunction, and specifically, increase glomerular filtration.

A method of estimating glomerular filtration rate of a feline can include measuring a blood sample of a feline for blood serum concentrations of pseudouridine and acetylthreonine, and optionally phenylacetylglutamine, and / or tryptophan, and also calculating a blood serum level product. The method can also include applying a feline factor as a multiple to the blood serum level product resulting in an estimated glomerular filtration rate. Calculating the blood serum level product can be based on a first weighted value based upon the blood serum concentration of pseudouridine, a second weighted value based upon the blood serum concentration of acetylthreonine,, an optional third weighted value based upon the blood serum concentration of phenylacetylglutamine, and an optional fourth weighted value based upon the blood serum concentration of tryptophan.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting physical examination indicators. These indicators include measurements of blood cells, glucose metabolism, tumor markers, urine components, anthropometric measurements, lipids, blood components, and tissue function. Preferably, these indicators include one or more selected from the following: glomerular filtration rate (eGFR), cystatin C, serum creatinine (SCr), blood urea nitrogen (BUN), timed up and go, light reaction time, fasting blood glucose (FBG), insulin-like growth factor (IGF), superoxide dismutase (SOD), insulin (INS), albumin (Alb), alkaline phosphatase (ALP), folic acid, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and high-sensitivity C-reactive protein (hs-CRP). More preferably, all of the aforementioned physical examination indicators are included. This invention also provides a physiological age prediction device applying the above-mentioned physiological age prediction model and a computer storage medium.

Systems, devices, and methods involve approaches for determining a calibration value for an individual, estimating a creatinine level using a chemical sensor (e.g., based on an optical property of a chemical sensor), and estimating a glomerular filtration rate (GFR) based, at least in part, on the calibration value and the creatinine level.